

FIGURE 1

mAb	Mean Fluorescence Intensity		% Gated	
	L1.2-CCR5	PBMC	L1.2-CCR5	PBMC
mouse IgG1	10	4	1	1
2D7	75	29	92	36
PA8	48	9	73	3
PA9	79	5	96	3
PA10	80	8	96	5
PA11	107	8	96	10
PA12	115	8	96	8
PA14	81	14	96	22

FIGURE 2

INHIBITOR COMBINATION	CONCENTRATION RATIO	ASSAY	COMBINATION INDEX	
			90% Inhibition	50% Inhibition
PA12:2D7	10:1	Entry	0.043	0.291
	2:1	Fusion	0.017	0.019
	10:1	Fusion	0.087	0.067
	50:1	Fusion	0.158	0.046
PA12:PA14	10:1	Entry	0.437	0.535
	10:1	Fusion	0.22	0.263
PA14:2D7	1:1	Entry	2.85	1.85
	1:1	Fusion	1.34	1.74
PA12:PA11	1:1	Entry	0.707	0.641
PA12:RANTES	1000:1	Fusion	0.331	0.156
PA14:RANTES	100:1	Fusion	1.6	1.37
2D7:RANTES	100:1	Fusion	0.972	0.962
PA12:CD4-IgG2	10:1	Fusion	0.3	0.31
PA14:CD4-IgG2	1:1	Fusion	0.957	0.566
2D7:CD4-IgG2	1:1	Fusion	1.127	0.302

FIGURE 3

	Epitopes	IC <sub>50</sub> values (μg/ml)			
		cell-cell fusion inhibition	viral entry inhibition	gp120-binding inhibition	calcium flux inhibition
PA8	Nt	-	-	-	-
PA9	Nt/ECL2	-	-	0.24	-
PA10	Nt/ECL2	-	-	0.13	-
PA11	Nt	25.5	-	0.33	-
PA12	Nt	10.0	-	0.24	-
PA14	Nt/ECL2	1.7	.024	1.58	6.4
2D7	ECL2	1.6	.026	1.38	45

FIGURE 4

	1	5	10	15	20	25	30																								
	M	D	Y	Q	V	S	S	P	I	Y	D	I	N	Y	Y	T	S	E	P	C	Q	K	I	N	K	Q	I	A	A	R	
2D7		92	52	90	nd	83	63	82	nd	48	50		40	90	90	88	111	49	57	43	21	37		52	92						105
PA8		118	153	78	nd	52	61	22	nd	4	2		0	153	2	45	100	47	52	39	41	37		53	24	134					93
PA9		16	13	0	nd	213	19	13	nd	10	10		19	62	52	23	72	39	52	39	45	39		55	18	145					140
PA10		21	14	0	nd	175	33	22	nd	14	8		15	101	39	94	85	47	47	45	45	39		53	13	133					126
PA11		30	32	0	nd	112	80	81	nd	20	22		49	78	88	85	82	47	47	52	48	49		47	22	148					141
PA12		30	32	0	nd	78	81	51	nd	24	12		49	78	88	86	86	84	84	49	46	38		52	12	83					143
PA14		9	86		nd	85	88	89	nd	57	48		53	78	84	88	76	80	64	34	88	52		76	46	89					153

	80				85				100						
	H	Y	A	A	A	Q	W	D	F	G	N	T	M	C	Q
2D7	70	89				49	130	40	86		53	72	82	0	72
PA8	88	92				49	118	32	115		98	88	85	10	29
PA9	51	81				27	81	16	159		138	89	57	0	43
PA10	57	83				38	139	18	133		112	97	33	0	26
PA11	59	81				38	91	25	78		30	94	74	10	50
PA12	63	77				54	91	30	77		76	79	102	25	55
PA14	70	79				84	83	23	86		47	89	80	8	73

	170				175				180				185				190										
	R	S	Q	K	E	G	L	H	Y	T	C	S	S	H	F	P	Y	S	Q	Y	Q	F	W	K	N	F	Q
2D7	12	55	17	0				102	84	65	0	83	95	53	22	22	80	92	73	49	21	23	30	81	7	45	102
PA8	36	46	50	15				165	48	151	38	90	100	51	41	15	90	128	73	50	48	95	94	46	4	52	52
PA9	26	28	24	15				52	13	0	25	93	112	27	48	27	79	135	75	74	13	51	48		12	15	55
PA10	46	59	50	19				36	21	0	25	84	98	32	50	18	77	82	83	30	16	59	45	16	153	79	73
PA11	187	53	15					48	138	130	37	78	95	26	48	28	91	99	101	53	24	74	15	23	56	92	
PA12	72	75						159	102	136	159	73	85	21	49	2	101	90	45	33	23		17	20	55	74	
PA14	11	85	88					80	24		9	109	83	32	28	38	90	93	88			79	16				

	285							270							275						
	Q	E	F	F	G	L	N	N	C	S	S	S	N	R	L	D	Q				
2D7		78	45	23			77	30	30	74	74	78	77				156				
PA8		78	25	9			43	44	40	85	74	73	88	99			98				
PA9		22	1				27	15	56	71	81	77	60	93			112				
PA10		24	25	4			64	30	53	93	103	45	74	72			128				
PA11		24	24	10			55	50	45	78	72	70	73	75			168				
PA12		25	25	11			53	53	40	83	72	99	92	78			131				
PA14		92	82				80	50	92	108	90	98	78				112				

76%-100+%  
51%-75%  
26%-50%  
0%-25%  
nd

Nt

ECL 1

ECL 2

ECL 3

5/11

FIGURE 5A






FIGURE 5B




7/11

FIGURE 6A



8/11

FIGURE 6B





9/11

FIGURE 6C




FIGURE 6D




FIGURE 7

